Combining Lonidamine and Cisplatin for Cancer Treatment
Author Information
Author(s): M De Cesare, G Pratesi, A Giusti, D Polizzi, F Zunino
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori
Hypothesis
Does the combination of lonidamine and cisplatin enhance the apoptotic response in human tumor xenografts?
Conclusion
The combination of lonidamine and cisplatin is more effective in inhibiting tumor growth and inducing apoptosis in sensitive tumors compared to cisplatin alone.
Supporting Evidence
- The combination of lonidamine and cisplatin significantly enhanced tumor volume inhibition compared to cisplatin alone.
- Lonidamine increased the apoptotic response induced by cisplatin in sensitive tumors.
- Phosphorylation of bcl-2 was associated with the efficacy of the drug combination.
Takeaway
This study found that using lonidamine with cisplatin helps kill cancer cells better than using cisplatin by itself.
Methodology
The study used human tumor xenografts in nude mice to assess the effects of lonidamine and cisplatin on tumor growth and apoptosis.
Limitations
The study focused only on specific carcinoma models and may not generalize to all tumor types.
Participant Demographics
Female athymic nude CD-1 mice were used for the experiments.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website